DESVENLAFAXINE

Peak

desvenlafaxine

NDAORALTABLET, EXTENDED RELEASE
Approved
Mar 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Norepinephrine Uptake Inhibitors

Pharmacologic Class:

Serotonin and Norepinephrine Reuptake Inhibitor

Clinical Trials (5)

NCT03432221N/AUnknown

Switching From SSRI to Desvenlafaxine on Cognitive Functioning

Started Apr 2018
36 enrolled
Major Depressive Disorder
NCT02819921Phase 4Terminated

Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen

Started Nov 2017
59 enrolled
Hot FlashesBreast Neoplasms
NCT02200406Phase 4Completed

Desvenlafaxine in Opioid-Dependent Patients

Started Jul 2014
18 enrolled
DepressionOpioid DependenceMethadone Treatment
NCT01537068Phase 4Completed

Desvenlafaxine vs. Placebo Treatment of Chronic Depression

Started Feb 2012
59 enrolled
Dysthymic DisorderDysthymiaChronic Depressive Disorder
NCT01443208Phase 1Completed

Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet

Started Nov 2011
36 enrolled
Major Depressive Disorder